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A Warm Farewell
A dozen years ago, not long after the founding of the
Association for Molecular Pathology (AMP), leaders of the
organization recognized the need for a dedicated journal
for the society. They sought a place in print that we
molecular diagnosticians could call our own and where
we could publish advances in a field that bridged basic
science and clinical diagnostics. The initial goals were
simple: to give equal value to new technology and new
discoveries, to provide careful validation and comparison
of clinical assays, and to promote our growing expertise,
as well as that of this fledgling organization, AMP. These
leaders also saw the value in partnering with a larger,
established professional group that could aid us in
quickly reaching beyond the borders of molecular pathol-
ogy to a broader range of pathology and medical profes-
sionals. Thus, in 1999, The Journal of Molecular Diagnos-
tics was launched (originally as The American Journal of
Pathology, Part B), in collaboration with the American
Society for Investigative Pathology. It has been a tremen-
dous honor to spend 11 years serving in a leadership role
for the JMD, and this issue will sadly be my last as
Editor-in-Chief. It is my belief that the JMD has fulfilled
those early goals, and my greatest desire is that it will
continue to thrive well into the future.
It has been exciting and rewarding to watch the Jour-
nal grow, along with AMP itself. Early on, AMP meetings
served as a focal point for bringing together those few of
us practicing molecular diagnostics (Who else could re-
late to the highs and lows of defining quality control and
assay reproducibility when dealing with radiolabeled
probes?). Over the years, the field has become much
more sophisticated in its technology, clinical applica-
tions, and assay standardization, and the articles pub-
lished within the JMD reflect this evolution. AMP has also
become active nationally and internationally, addressing
a variety of regulatory, educational, and other issues, and
in parallel, the JMD has seen an increasing number of
position papers from the society and other professional
groups addressing many of the same issues of impor-
tance to our colleagues and trainees (see the Special
Report on competency-based education in this issue).
We are also at the point where an increasing number of
submitted manuscripts no longer fit squarely into the
traditional subdivisions of our society (Solid Tumors,
Hematopathology, Genetics, and Infectious Disease)
but instead fall into new areas, which will require on-
going evolution on the part of the JMD. Molecular
diagnostics has grown in amazing and unanticipated
directions and will continue to do so in the years to
come, as will the JMD.
I am very proud to see the progress that has been
made by the JMD. Submissions have risen again this
past year, and the quality of papers continues to go up.
We have successfully moved from a quarterly to bi-
monthly publication, without a drop in quality or number
of articles per issue. We continue to attract an increasing
number of timely Reviews, as well as Commentaries on
key articles, published within each issue. And perhaps
the most quantitative, and scrutinized, measure of our
success, the impact factor, has risen to an outstanding
3.643 (2008 JCR). The JMD has clearly established itself
as the premier journal in the field of molecular diagnos-
tics. Again, changes lie ahead, as we anticipate the
revolution in scientific publishing that is coming: elec-
tronic and publish-ahead-of-print article delivery are just
the beginning—I expect to have JMD content available
instantaneously in my pocket in the not-so-distant future.
Despite the many differences the future will bring to sci-
entific publishing, the central purpose will remain un-
changed: journals have a responsibility to provide effi-
cient, unbiased peer review of scientific work, to relay
top-quality, novel results to readers as quickly as possi-
ble, and to share useful information to advance the field
as a whole.
Thinking back, I am amazed by the responsibility and
trust bestowed on me—by the Joint Journal Oversight
Committee, the two societies, and their members, and by
the innumerable authors who have entrusted our editorial
team of Associate Editors and Editorial Board members
with the task of evaluating their hard work. I hope we have
handled each manuscript as we would our own, with
fairness and a great deal of personal attention. We have
strived to be open and unbiased, while maintaining and
even raising the quality of published manuscripts. Occa-
sionally issues did arise, and I hope that we handled
these fairly and kindly—it is not easy to deliver negative
news to one’s respected colleagues. But this difficult job
was made easier by the professionalism and grace
shown by authors with whom we worked. The past years
have been extremely gratifying, and I have learned and
grown far more in knowledge and experience than I had
ever imagined. While the JMD was envisioned to be a
benefit to AMP, its members, and practitioners of molec-
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ular diagnostics worldwide, I truly feel as though the
primary beneficiary has been me.
As I say goodbye to my editorial responsibilities, my
deepest thanks go out to all who have worked with me
during my tenure. In particular, Nelson Fausto, who
served as the first JMD Editor-in-Chief, guided me as I
learned the ropes of editorial leadership as Senior Asso-
ciate Editor. I thank the many Associate Editors who
toiled tirelessly with me to oversee the review process
and assist in manuscript decision making. I am also
grateful to the three Managing Editors who have directed
the JMD through its evolution: Priscilla Markwood, Maria
Giorla, and Audra Cox. Finally, I am very appreciative of
the leadership of the two societies for allowing me the
editorial freedom to take the JMD in exciting directions.
It is now time for a new leader to steer the direction of
the JMD. So I extend my most enthusiastic wishes to
Timothy O’Leary in his endeavors with the JMD; his lead-
ership skills and strong molecular background make him
an excellent choice to pilot the JMD into the future—a
future that is very bright indeed. And although I will no
longer be behind the helm, I will still read it cover to cover
for years to come!
Karen L. Kaul, M.D., Ph.D.
Editor-in-Chief
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